Clinical trial

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Name
MW-III-BURN-2-001
Description
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
Trial arms
Trial start
2022-03-11
Estimated PCD
2024-12-22
Trial end
2024-12-22
Status
Recruiting
Phase
Early phase I
Treatment
Investigational Drug, MW-III
Topical application, twice a day
Arms:
Investigational Drug, MW-III
Silvadene® Cream 1% [Silver Sulfadiazine]
Topical application, twice a day
Arms:
Standard of care
Size
60
Primary endpoint
Time to healing (≥95% re-epithelialization) of the partial thickness target burn.
28 days Treatment Period
Eligibility criteria
Inclusion Criteria: 1. Adults, 18 years of age or older on the day of signing the informed consent. 2. Thermal Burns not exceeding a total body surface area (TBSA) OF 25%, with at least one partial thickness burn of 0.5% TBSA or greater. If full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% TBSA. Note: TBSA excludes areas of superficial (first degree) burns. 3. Able and willing to give informed consent and comply with study procedures. Exclusion Criteria: 1. Any burn that at screening is: 1. infected. 2. circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome. 3. partial thickness that is likely, in the judgment of the Investigator, to require grafting within 72 hours, or other non-protocol intervention. 2. Severe inhalation injury or other significant non-burn trauma.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}
Updated at
2024-02-08

1 organization

2 products

1 indication

Product
MW-III
Indication
Burns
Organization
Skingenix